| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
|
N Engl J Med
|
2002
|
5.65
|
|
2
|
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
|
Am J Psychiatry
|
2009
|
3.26
|
|
3
|
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
|
J Clin Psychiatry
|
2005
|
2.39
|
|
4
|
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
|
Schizophr Res
|
2006
|
1.93
|
|
5
|
The heterogeneity of schizophrenia in disease states.
|
Schizophr Res
|
2004
|
1.04
|
|
6
|
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
|
Bipolar Disord
|
2009
|
0.97
|
|
7
|
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
|
BMC Med
|
2008
|
0.93
|
|
8
|
Methods for claims-based pharmacoeconomic studies in psychosis.
|
Pharmacoeconomics
|
2002
|
0.89
|
|
9
|
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
|
Int Psychogeriatr
|
2005
|
0.89
|
|
10
|
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.
|
J Psychiatr Res
|
2008
|
0.88
|
|
11
|
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
|
Clin Ther
|
2003
|
0.87
|
|
12
|
Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study.
|
Ann Gen Psychiatry
|
2009
|
0.86
|
|
13
|
The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
|
J Nerv Ment Dis
|
2007
|
0.84
|
|
14
|
Regulatory issues for health-related quality of life--PhRMA Health Outcomes Committee workshop, 1999.
|
Value Health
|
2002
|
0.82
|
|
15
|
Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.
|
Pharmacoeconomics
|
2002
|
0.78
|
|
16
|
Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia.
|
Hum Psychopharmacol
|
2007
|
0.75
|
|
17
|
Methodological issues in a comparative study of ziprasidone and risperidone.
|
J Clin Psychiatry
|
2006
|
0.75
|
|
18
|
Early Alzheimer's disease.
|
N Engl J Med
|
2004
|
0.75
|
|
19
|
Letter to the editor.
|
J Minim Invasive Gynecol
|
2010
|
0.75
|
|
20
|
Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
|
J Affect Disord
|
2009
|
0.75
|
|
21
|
Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trials.
|
Psychopharmacol Bull
|
2008
|
0.75
|